Skip to main content

News & Announcements

MPV (Monkeypox) Information

Monkeypox and HIV

Monkeypox Updates for Division of HIV and STI Programs (DHSP) Partners

 


Coronavirus (COVID-19) Information

COVID-19 Vaccine and Booster Shots for People with HIV

The U.S. Department of Health and Human Services (HHS) recommends that people living with HIV should receive the COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) also recommends people who are immunocompromised, including people with advanced or untreated HIV, should receive an additional third dose at least 28 days after a second dose of Pfizer or Moderna.

With the authorization of booster vaccine shots for COVID-19, HHS recommends that people living with HIV consider receiving a booster shot after six months of initial vaccination for those who received Pfizer or Moderna, and at least two months after initial vaccination for those who received Johnson & Johnson. People living with HIV should talk to their healthcare provider about getting a COVID-19 booster shot.

To find a COVID-19 vaccine location, visit: Vaccines.gov.

For more information about the COVID-19 vaccine, visit:

Emergency Use Authorization (EUA) of Evusheld™ for COVID-19

In December 2021, the Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Evusheld™ (tixagevimab co-packaged with cligavimab), SARS-CoV-2 spike protein-directed attachment inhibitor, for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older who weigh at least 40 kg):

  • Who are not currently infected with COVID-19 and who have not had a known recent exposure to an individual infected with COVID-19 and
    • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
    • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestation of symptomatize HIV) is considered a medical condition that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination.

Provider Information

MDHHS encourages those who provide HIV care or prevention services to consider Evusheld™ for patients who are eligible. For more information on Evusheld™, review: Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld (FDA.gov).

For information from MDHHS on the prioritization and scarce resource allocation of Evusheld™, review: Prioritization and Scarce Resource Allocation of Evusheld for COVID-19 Pre-Exposure Prophylaxis in Certain High Risk Individuals.

Patient Information

Patients can review the Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization of Evusheld for (COVID-19) (FDA.gov).

For additional information on COVID-19 therapy, providers and patients should visit: Michigan.gov/COVIDtherapy (Michigan Department of Health and Human Services).

 

Additional HIV-Related Resources

  • Interim Guidance for COVID-19 and Persons with HIV is now available. The guidance, which was developed collectively by the HHS Antiretroviral and Opportunistic Infections Guidelines Panels, working groups of the Office of AIDS Research Advisory Council, is intended for health care providers and people living with HIV in the United States.
     
  • HRSA is working to keep Ryan White HIV/AIDS Program recipients, subrecipients, and partners updated on the latest information regarding COVID-19.  As part of that effort, HRSA's HIV/AIDS Bureau (HAB) has launched a Frequently Asked Question (FAQ) webpage on the HAB website, which HAB is monitoring and updating as new information is made available.
     
  • Centers for Disease Control and Prevention (CDC) has made available a Frequently Asked Questions (FAQs) about HIV and coronavirus disease 2019 (COVID-19). The new resource addresses concerns related to COVID-19 and HIV and highlights how people with HIV can protect their health.
  • NASTAD has compiled a summary of other COVID-19 related resources and updates on a newly launched "Updates and Resources" website.
  • Fact Sheets
    NASTAD has produced fact sheets about Medicaid, Medicare, and private insurance policies expanding access to health care for people living with HIV and viral hepatitis during the COVID-19 public health emergency. The resources explain policies and protections that can help ensure safe and comprehensive access to health care for people living with HIV and viral hepatitis during the ongoing public health crisis, and include frequently asked questions for programs working with clients.

 

Additional STI-Related Resources

 


HIV & STI News

National HIV Testing Day | June 27, 2022

Taking an HIV test is taking care of you. Knowing your status gives you powerful information to help stay healthy. MDHHS encourages residents to make HIV testing a part of their life in support of National HIV Testing Day.

Learn more about HIV testing options: Let's Stop HIV Together - HIV Testing
 

National Asian and Pacific Islander HIV/AIDS Awareness Day | May 19, 2022

National Asian and Pacific Islander HIV/AIDS Awareness Day is a day to combat stigma in Asian and Pacific Islander communities. When we reduce HIV stigma and promote prevention, testing, and treatment, we can stop HIV together. 

For additional information, visit: Let's Stop HIV Together
 

National Transgender HIV Testing Day | April 18, 2022

National Transgender HIV Testing Day recognizes the importance of routine HIV testing and status awareness.

Learn more about the focus on prevention and treatment efforts among transgender and gender non-binary people: HIV and Transgender People
 

Reported Cases of Congenital Syphillis Increased in 2021

Michigan Radio interview with Michigan's Chief Medical Executive Dr. Natasha Bagdasarian: Syphillis cases in newborns increased steeply in Michigan last year
 

National STD Awareness Week | April 10-16, 2022

2022 National STD Awareness WeekNational STD Awareness Week is an opportunity for us to highlight and raise awareness around STDs/STIs and how they impact our lives; reduce STI related stigma, fear, and discrimination; and ensure that people have the tools and knowledge to test, treat, and prevent STIs.

As a part of STD Awareness Week, MDHHS urges Michiganders to get tested for STIs.
 

Do you know the numbers surrounding HIV in Michigan?

Change the numbers. Change your future. Find HIV testing locations and resources.Currently, 1.2 million Americans are living with HIV. In Michigan, it is estimated that 1 in 8 people are unaware of their HIV status. Early detection, intervention, and treatment can reduce the risk of transmission by 93%.

To learn more and find HIV testing locations, please visit: Change the numbers. Change your future.

 


Clinical Alerts

Notification of Rapid Rise in Congenital Syphilis

In recent years, rates of primary and secondary (PS) syphilis in women have increased substantially across the United States; 21% from 2019-2020 and 147% between 2016-2020. The data suggest a shift from largely affecting men who have sex with men, to a heterosexual syphilis epidemic. Michigan is following these trends with 21% of PS syphilis cases reported in 2021 occurring among women of childbearing age.

As rates of syphilis in women continue to increase, so do reported cases of congenital syphilis (CS). Rates of CS in the US have increased every year since 2013. Michigan has seen a 320% increase since 2017. In 2021, 42 cases of congenital syphilis were reported in Michigan reaching the highest numbers since the early 1990’s. A pregnant woman can transmit syphilis to her child during any stage of syphilis and any trimester of pregnancy. However, the risk of transmission is highest if the mother has been recently infected.

Syphilis symptoms can present in several stages. The primary syphilis chancre is painless and may not be noted by infected persons, as it resolves even without treatment. Most patients who seek care do so with secondary syphilis symptoms that include a rash, often on the palms and soles, condyloma lata, and lymphadenopathy. Left untreated, syphilis can cause cardiac system abnormalities and neurological symptoms in later stages.

To identify cases early in infection and prevent further transmission, clinicians are requested to follow these recommendations:

  • Test all women who present with other Sexually Transmitted Infections (STIs) or have risk factors for STIs.
  • All pregnant women residing in Michigan should be screened for syphilis at their first prenatal appointment and again in the third trimester between 28-32 weeks, as required by State Law.
  • Infants should not be discharged from the hospital, unless the mother has been tested for syphilis at least once during pregnancy and preferably again at delivery.

Treatment for syphilis should be appropriate for the diagnosed stage with one to three shots of benzathine penicillin G, 2.4 million units IM. (see CDC Treatment Guidelines - Syphilis During Pregnancy). Infants born to untreated mothers, or mothers with inadequate treatment (including those treated CDC Treatment Guidelines - Congenital Syphilis).

For more information on congenital syphilis please contact Aleigha Phillips, Congenital Syphilis Coordinator. For other syphilis questions, contact Karen Lightheart, Statewide Provider Liaison.

 

2021 Sexually Transmitted Infections Treatment Guidelines

The Centers for Disease Control and Prevention (CDC) released Sexually Transmitted Infections Treatment Guidelines, 2021. This document provides current evidence-based diagnostic, management, and treatment recommendations, and serves as a source of clinical guidance for managing sexually transmitted infections (STIs). The new guidelines include notable updates from the previous 2015 guidance, including:

  • updated treatment recommendations for chlamydia, trichomoniasis, and pelvic inflammatory disease;
  • updated treatment recommendations for uncomplicated gonorrhea in neonates, children, and other specific clinical situations (e.g., proctitis, epididymitis, sexual assault), which builds on broader treatment changes published in Morbidity and Mortality Weekly Report;
  • information on FDA-cleared diagnostic tests for Mycoplasma genitalium and rectal and pharyngeal chlamydia and gonorrhea;
  • expanded risk factors for syphilis testing among pregnant patients;
  • recommended two-step serologic testing for diagnosing genital herpes simplex virus;
  • harmonized recommendations for human papillomavirus vaccination with the Advisory Committee on Immunization Practices; and
  • recommended universal hepatitis C testing in alignment with CDC's 2020 hepatitis C testing recommendations.

 

Chlamydia, Gonorrhea, and Trichomoniasis Expedited Partner Therapy (EPT)

Michigan Public Act 525 of 2014 (MCL 333.5110) authorized the use of expedited partner therapy (EPT) for certain sexually transmitted infections as designated by the state health department. In April 2020, the Michigan Department of Health and Human Services designated chlamydia, gonorrhea, and trichomoniasis as infections for which the use of EPT is appropriate.

 


Updates for Division of HIV and STI Programs (DHSP) Partners

 

The Division of HIV and STI Programs (DHSP) quarterly newsletter and other related updates provide important information about HIV and STIs in Michigan. Below you will find previous issues of the newsletter and other updates for DHSP Partners:

    • June 2022 Newsletter
      In this newsletter, you will find information about DHSP and the Michigan HIV/AIDS Council (MHAC) celebrating Pride Month, the latest from the HIV/STI Epidemiologists, information about upcoming HIV/STI trainings and events including registration for the State of Michigan HIV/STI Conference, and more. Read more...
       
    • March 2022 Newsletter
      In this newsletter, you will find information about updated CDC Clinical Practice Guidelines for PrEP, an update on MIDASH (Michigan Integrated Data Application for STI and HIV), information on the 2022 Michigan Clinical Nursing Conference for HIV and STI Care, information about National STD Awareness Week and National LGBTQ Health Awareness Week, and more. Read more...
       
    • December 2021 Newsletter
      In this newsletter, you will find a note from Division of HIV and STI Programs Director Katie Macomber, information on the concerning increase in female syphilis, a preview of the 2022 HIV/STI Training Calendar, and more. Read more...
       
    • SHOARS is Live!
      The STI/HIV Operations and Resource System (SHOARS) officially launched on November 29, 2021. SHOARS allows DHSP Partners to engage with the diverse resources of the Division of HIV and STI Programs (DHSP). SHOARS improves the relationship between DHSP and DHSP Partners to efficiently provide services for Michiganders who are at risk and/or living with HIV & STIs. Learn more about SHOARS...
       
    • 2020 HIV and STI Data and Statistics Reports Available
      HIV and STI Data and Statistics reports are now available with the most recent surveillance data through 2020. These reports include information by county or local health department that highlights priority populations by age, race, sex, and other demographic characteristics. Read more...

    Email Updates

    To sign up for the DHSP newsletter and other HIV and STI related updates, please enter your email address below.